FDA clears Medtronics new left-heart leads

Justine Varieur Cadet | | Health Imaging | Screening
The FDA has approved Medtronic’s Attain Ability Plus and the Attain Ability Straight left-heart leads for use with cardiac resynchronization therapy (CRT) devices in treating heart failure patients.

The two new dual-electrode leads are the latest offering in a line of left-heart lead options that fit through the Attain Select II sub-selection catheter delivery system and navigate patient vein anatomies during the CRT implant procedure, according to the Minneapolis-based company.

The product is immediately available in the U.S.

Justine Varieur Cadet

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.